US Pharma MarketingDeaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease
Three patient deaths in Novartis Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and…
Many researchers believe cancer cell therapies called CAR-Ts could shift the treatment paradigm for patients with autoimmune disease. But three recently disclosed deaths in Novartis’ clinical trials serve as a stark reminder that the modality ...
Source: Endpoints News